Evidence-Based Treatment of Patients with Common Nail Disorders
213402134021340
At the 2024 ODAC Dermatology, Aesthetic & Surgical Conference, we had the opportunity to learn about treating common nail disorders from Dr. Molly A. Hinshaw, MD, FAAD, Director of Nail Clinic, Section Chief of Dermatopathology, and Professor of Dermatology at the University of Wisconsin School of Medicine. Nail conditions can markedly decrease the quality of life for patients not only due to …
At the 2024 ODAC Dermatology, Aesthetic & Surgical Conference, we had the opportunity to learn about treating common nail disorders from Dr. Molly A. Hinshaw, MD, FAAD, Director of Nail Clinic, Section Chief of Dermatopathology, and Professor of Dermatology at the University of Wisconsin School of Medicine. Nail conditions can markedly decrease the quality of life for patients not only due to … Continue reading "Evidence-Based Treatment of Patients with Common Nail Disorders"
Next Steps in Derm, in partnership with Skin of Color Update, interviewed Dr. Shari Lipner, director of the Nail Division at the New York-Presbyterian Hospital/Weill Cornell Medical Center. Hear the results of Dr. Lipner’s retrospective study on time to diagnosis in patients with skin of color who have nail psoriasis. Find out why the clinical examination is especially important. Learn how derm … 
Bimekizumab (Bimzelx®) is a new injectable medication FDA approved for plaque psoriasis. It is the first and only FDA approved IL-17A and IL-17F inhibitor for this disease, but is also being used as an off-label option for other conditions including psoriatic arthritis and hidradenitis suppurativa. This Therapeutic Cheat Sheet will focus on the on and off label uses of bimekizumab.
Bimekizuma … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed to Dr. Molly Hinshaw, professor of dermatology, section chief of dermatopathology and director of the nail clinic at the University of Wisconsin School of Medicine and Public Health. Watch as Dr. Hinshaw shares her tips for performing nail biopsies. Find out what’s the safest and most usef … 
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica … 